Boothbay Fund Management’s Soleno Therapeutics SLNO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-124,519
| Closed | -$4.17M | – | 2597 |
|
|
2026
Q1 | $4.17M | Buy |
124,519
+80,657
| +184% | +$3.16M | 0.05% | 367 |
|
|
2025
Q4 | $2.03M | Buy |
43,862
+9,632
| +28% | +$528K | 0.03% | 557 |
|
|
2025
Q3 | $2.31M | Buy |
34,230
+24,230
| +242% | +$1.8M | 0.03% | 532 |
|
|
2025
Q2 | $838K | Sell |
10,000
-3,750
| -27% | -$281K | 0.02% | 744 |
|
|
2025
Q1 | $982K | Buy |
+13,750
| New | +$670K | 0.03% | 642 |
|
|
2024
Q4 | – | Sell |
-51,710
| Closed | -$2.68M | – | 1880 |
|
|
2024
Q3 | $2.61M | Sell |
51,710
-52,310
| -50% | -$2.5M | 0.06% | 443 |
|
|
2024
Q2 | $4.24M | Sell |
104,020
-28,011
| -21% | -$1.19M | 0.1% | 276 |
|
|
2024
Q1 | $5.65M | Buy |
132,031
+8,892
| +7% | +$402K | 0.11% | 192 |
|
|
2023
Q4 | $4.96M | Buy |
123,139
+14,762
| +14% | +$420K | 0.13% | 200 |
|
|
2023
Q3 | $3.2M | Buy |
+108,377
| New | +$656K | 0.08% | 354 |
|
|
2022
Q2 | – | Sell |
-16,810
| Closed | -$56K | – | 2629 |
|
|
2022
Q1 | $56K | Buy |
16,810
+16,000
| +1,975% | +$82.8K | ﹤0.01% | 2166 |
|
|
2021
Q4 | $5K | Hold |
810
| – | – | ﹤0.01% | 1807 |
|
|
2021
Q3 | $11K | Sell |
810
-51
| -6% | -$711 | ﹤0.01% | 1853 |
|
|
2021
Q2 | $15K | Hold |
861
| – | – | ﹤0.01% | 1804 |
|
|
2021
Q1 | $16K | Hold |
861
| – | – | ﹤0.01% | 1496 |
|
|
2020
Q4 | $25K | Buy |
+861
| New | +$24.8K | ﹤0.01% | 1199 |
|
|
2020
Q3 | – | Sell |
-2,832
| Closed | -$94K | – | 1199 |
|
|
2020
Q2 | $94K | Buy |
+2,832
| New | +$123K | 0.01% | 883 |
|
Boothbay Fund Management's SLNO Position: Q2 2026 in Review
Boothbay Fund Management sold out of Soleno Therapeutics (SLNO) in Q2 2026, closing a stake of 124,519 shares — an estimated $4.17M sold.
Boothbay Fund Management first reported a position in SLNO in Q2 2020 and held it in 17 quarters. The position peaked at $5.65M in Q1 2024. 0 funds tracked by Wall St. Rank hold SLNO as of Q2 2026.
- Boothbay Fund Management reported no remaining Soleno Therapeutics position as of Q2 2026 after selling out during the quarter.
- Boothbay Fund Management sold 124,519 Soleno Therapeutics shares in Q2 2026, an estimated $4.17M.
- Boothbay Fund Management first reported a position in Soleno Therapeutics in Q2 2020 and held it in 17 quarters.
- Boothbay Fund Management's Soleno Therapeutics position peaked at $5.65M in Q1 2024.
- 0 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q2 2026.
Based on Boothbay Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.